GMI-1271

Phase 1Small molecule

GGlycoMimetics Incorporated

GMI-1271 is one of 62 small molecule programs targeting Venous thrombosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThrombosisActive, not recruiting

Multiple MyelomaActive, not recruiting

Venous ThrombosisPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 7

Abecma

Bristol-Myers Squibb

Preclinical

4 8

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

2 9

Florbetaben

LLife Molecular Imaging GmbH

Preclinical

1 10

GMI-1271

GGlycoMimetics Incorporated

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult Subject2 trials

A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects

Completed·GGlycoMimetics Incorporated·Phase 1·NCT02703051·54 enrolled

Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Completed·GGlycoMimetics Incorporated·Phase 1·NCT02271113·32 enrolled

Multiple Myeloma1 trial

A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

Completed·GGlycoMimetics Incorporated·Phase 1·NCT02811822·10 enrolled

Chemotherapy1 trial

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Completed·GGlycoMimetics Incorporated·Phase 1/2·NCT02306291·91 enrolled

Single Dose1 trial

Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers

Completed·GGlycoMimetics Incorporated·Phase 1·NCT02168595·28 enrolled

Venous thrombosis1 trial

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

Terminated·GGlycoMimetics Incorporated·Phase 1/2·NCT02744833·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for GMI-1271. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GMI-1271 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GMI-1271. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GlycoMimetics Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGlycoMimetics Incorporated

GMI-1271

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Adult Subject2 trials

Multiple Myeloma1 trial

Chemotherapy1 trial

Single Dose1 trial

Venous thrombosis1 trial

References

Drug Info

Quick Facts

Related News